Cutaneous T Cell Lymphoma: Clinical Trials

11 trials for Cutaneous T Cell Lymphoma, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

5 completed, 2 unknown, 1 active not recruiting, 1 not yet recruiting. 11 Phase 1, 2 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 111Completed 5, Unknown 2, Active not recruiting 1, Not yet recruiting 1, Recruiting 1, Suspended 1
Phase 22Completed 2

Follow Cutaneous T Cell Lymphoma: new trials by email Literature Review of Cutaneous T Cell Lymphoma trials Research Report on Cutaneous T Cell Lymphoma

Trials (filtered) newest first · largest first

All 11 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ropeginterferon in Patients w/Cutaneous T-Cell Lymphoma (CTCL)
Ropeginterferon alfa-2b - Cutaneous T Cell Lymphoma
Phase 1RecruitingH. Lee Moffitt Cancer Center and Research Institute382025-08-272026-04-01
A Clinical Trial in Adults With Non-Hodgkin Lymphoma (NHL), With a Particular Emphasis on Cutaneous T Cell Lymphoma (CTCL), Testing the Safety and Activity of a Novel Drug to Inhibit a Protein Called Tumor Necrosis Factor Receptor 2 That Drives Both Lymphoma Growth and Escape of the Immune System
BITR2101 - NHL, Cutaneous T Cell Lymphoma
Phase 1Not yet recruitingBoston Immune Technologies and Therapeutics372025-08-012025-07-08
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
Mogamulizumab, Brentuximab vedotin - Cutaneous T Cell Lymphoma, Mycosis Fungoides
Phase 1SuspendedUniversity of Alabama at Birmingham102023-05-012026-06-15
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
SIM1811-03 or in combination with Sintilimab injectiont - Advanced Solid Tumor, Cutaneous T Cell Lymphoma
Phase 1UnknownJiangsu Simcere Biologics Co., Ltd2552022-03-062023-09-21
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
[14C]-resminostat - Cutaneous T Cell Lymphoma, Mycosis Fungoides
Phase 1Completed4SC AG52021-10-122022-02-18
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
GZ17-6.02, Capecitabine - Advanced Cancer, Gastric Cancer
Phase 1UnknownGenzada Pharmaceuticals USA, Inc.1272019-03-012022-12-23
Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL
ATLCAR.CD30.CCR4 cells, ALTCAR.CD30 cells, Bendamustine - Lymphoma, Immune System Diseases
Phase 1Active not recruitingUNC Lineberger Comprehensive Cancer Center432018-10-292026-06-12
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
Tinostamustine - Hematological Malignancies, Multiple Myeloma
Phase 1CompletedMundipharma Research Limited1062016-04-142024-07-25
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
Micro needle array-Doxorubicin (MNA-D) - Cutaneous T Cell Lymphoma
Phase 1CompletedFalo, Louis, MD202016-03-092024-08-09
Topical Resiquimod for the Treatment of Early Stage Cutaneous T Cell Lymphoma (CTCL)
Topical resiquimod 0.06%, topical resiquimod 0.03% - Cutaneous T Cell Lymphoma
Phase 1 / Phase 2CompletedAbramson Cancer Center at Penn Medicine132012-02-012019-08-13
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
RAD001 (Everolimus) - Peripheral T Cell Lymphoma Unspecified, Anaplastic Large Cell Lymphoma, ALK-negative
Phase 1 / Phase 2CompletedSamsung Medical Center462010-07-012015-03-03

Narrower conditions

Lymphoma, T-Cell, Cutaneous (11)  ·  Mycosis Fungoides (4)  ·  Lymphoma (2)  ·  Sezary Syndrome (2)  ·  Breast Neoplasms (1)  ·  Carcinoma, Basal Cell (1)  ·  Colonic Neoplasms (1)  ·  Hematologic Neoplasms (1)  ·  Hodgkin Disease (1)  ·  Immune System Diseases (1)  ·  Immunoblastic Lymphadenopathy (1)  ·  Immunoproliferative Disorders (1)  ·  Lymphatic Diseases (1)  ·  Lymphoma, Large-Cell, Anaplastic (1)  ·  Lymphoma, T-Cell (1)

Broader conditions

Hemic and Lymphatic Diseases (11)  ·  Lymphoma, Non-Hodgkin (11)  ·  Neoplasms by Histologic Type (11)  ·  Immune System Diseases (10)  ·  Immunoproliferative Disorders (10)  ·  Lymphatic Diseases (10)  ·  Lymphoma, T-Cell (10)  ·  Lymphoproliferative Disorders (10)  ·  Neoplasms (10)  ·  Lymphoma (9)  ·  Neoplasms by Site (2)  ·  Blood Protein Disorders (1)  ·  Breast Diseases (1)  ·  Carcinoma (1)  ·  Carcinoma, Squamous Cell (1)

Interventions

Doxorubicin (2)  ·  Bendamustine Hydrochloride (1)  ·  Brentuximab Vedotin (1)  ·  Capecitabine (1)  ·  Cyclophosphamide (1)  ·  Everolimus (1)  ·  Prednisolone (1)  ·  Transdermal Patch (1)  ·  Vincristine (1)  ·  fludarabine (1)  ·  mogamulizumab (1)  ·  tinostamustine (1)

Sponsors

4SC AG (1)  ·  Abramson Cancer Center at Penn Medicine (1)  ·  Boston Immune Technologies and Therapeutics (1)  ·  Falo, Louis, MD (1)  ·  Genzada Pharmaceuticals USA, Inc. (1)  ·  H. Lee Moffitt Cancer Center and Research Institute (1)  ·  Jiangsu Simcere Biologics Co., Ltd (1)  ·  Mundipharma Research Limited (1)  ·  Samsung Medical Center (1)  ·  UNC Lineberger Comprehensive Cancer Center (1)  ·  University of Alabama at Birmingham (1)

Countries

United States (7)  ·  China (1)  ·  France (1)  ·  Germany (1)  ·  Italy (1)  ·  Netherlands (1)  ·  South Korea (1)  ·  Spain (1)  ·  Switzerland (1)  ·  United Kingdom (1)

Top investigators

Alain H Rook, M.D. (1)  ·  Kathryn Gazarik (1)  ·  Lauren Shea, M.D. (1)  ·  Natalie Grover, MD (1)  ·  Oleg E Akilov, MD, PhD (1)  ·  Pier L Zinzani, MD,PhD (1)  ·  Ruihua Xu, MD (1)  ·  Won Seog Kim, MD, PhD (1)  ·  Yumeng Zhang, MD (1)

Results publications

PMID 26228486, PMID 35276694, PMID 37589506, PMID 38758815, PMID 39617826, PMID 39821757

NIH funding

R01CA247497 (1)